Filing Flows

Filing Flows › Companies › Harvard Apparatus Regenerative Technology › Cash flow

Harvard Apparatus Regenerative Technology cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$569K in Q2 2026 · −$3.6M over twelve months

Operating cash flow−$569K
Free cash flow−$569K
Cash conversion cycle-111 days

Analysis

In Q2 2026, Harvard Apparatus Regenerative Technology generated −$569K of operating cash flow. That is $372K more than in Q2 2025 (−$941K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$3.6M; the largest uses were operating cash flow ($3.6M); besides operations, cash came from other financing ($3.2M); the cash balance fell by $435K.

Operating cash flow was −$569K against net income of −$1.7M. The largest differences: payables +$518K, deferred revenue +$263K, stock-based pay +$223K.

Its cash conversion cycle was -111 days (receivables 3 + inventory 2 − payables 116): suppliers fund its working capital.

Free cash flow

Harvard Apparatus Regenerative Technology: free cash flow by quarterHarvard Apparatus Regenerative Technology: free cash flow by quarter−$1.5MQ3 2024−$1.1MQ4 2024−$758KQ1 2025−$941KQ2 2025−$1.5MQ3 2025−$664KQ4 2025−$937KQ1 2026−$569KQ2 2026
Operating cash flow less capital spending.
Harvard Apparatus Regenerative Technology: operating cash flow against capital spendingHarvard Apparatus Regenerative Technology: operating cash flow against capital spendingOperating cash flowCapital spending−$1.5M$0Q3 2024−$1.1M$0Q4 2024−$758K$0Q1 2025−$941K$0Q2 2025−$1.5M$0Q3 2025−$664K$0Q4 2025−$937K$0Q1 2026−$569K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$569K, Capital spending $0.

Capital allocation, year by year

Harvard Apparatus Regenerative Technology: where the cash came from (up) and went (down), by fiscal yearHarvard Apparatus Regenerative Technology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$2.6MFY2021FY2022: Operating cash flow −$5.1MFY2022: Shares issued $5.1MFY2022: Capital spending −$5K$5.1MFY2022FY2023: Operating cash flow −$6.9MFY2023: Shares issued $6.1MFY2023: Capital spending −$11K$6.1MFY2023FY2024: Operating cash flow −$4.9MFY2024: Shares issued $6.5M$6.5MFY2024FY2025: Operating cash flow −$3.8MFY2025: Shares issued $2.7M$2.7MFY2025
Over these 5 years operating cash flow totalled −$23.4M; the largest uses were operating cash flow ($23.4M) and capital spending ($16K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$351K
Debtnone
Net cash$351K
Cash runway1 month

Harvard Apparatus Regenerative Technology is burning cash: its operations consume cash, a free cash flow of −$3.6M a year at the current rate against $351K of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

Harvard Apparatus Regenerative Technology: sources (+) and uses (−) of cash, Q2 2026Harvard Apparatus Regenerative Technology: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$569KNot reconciled$500KCash drawn (+) / kept (−)$68KExchange rates$1K
Harvard Apparatus Regenerative Technology: sources (+) and uses (−) of cash, TTM to Q2 2026Harvard Apparatus Regenerative Technology: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$3.6MOther financing$3.2MCash drawn (+) / kept (−)$435K

From profit to cash

Harvard Apparatus Regenerative Technology: net income to operating cash flow, Q2 2026Harvard Apparatus Regenerative Technology: net income to operating cash flow, Q2 2026Net income−$1.7MDepreciation & amortization$1KStock-based pay$223KReceivables$7KInventory$15KPayables$518KDeferred revenue$263KPrepaid and other assets$59KOperating cash flow−$569K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202632116-111
Q1 202667151-138
Q4 202549177-165
Q3 2025320273-250
Q2 2025111122-109
Q1 20252351751237-827
Q4 20244151252-160

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$569K——$68K−$569K
Q1 2026−$937K$500K—$933K−$937K
Q4 2025−$664K—$700K−$33K−$664K
Q3 2025−$1.5M—$2.0M−$533K−$1.5M
Q2 2025−$941K——$942K−$941K
Q1 2025−$758K——$758K−$758K
Q4 2024−$1.1M——$1.1M−$1.1M
Q3 2024−$1.5M—$5.0M−$3.5M−$1.5M

Harvard Apparatus Regenerative Technology: income statement and cash flow

Harvard Apparatus Regenerative Technology, Q2 2026: revenue $414K (+31% year over year), operating margin -408.7%. The chart follows the revenue to costs, profit and cash.

Harvard Apparatus Regenerative Technology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.